We are glad to announce that a further research protocol is activated and currently available for patients with Malignant Pleural Mesothelioma.
The title of this research protocol is: "Phase II study of the combination of gemcitabine and imatinib mesylate in patients with malignant pleural mesothelioma pre-treated with pemetrexed."
In particular, it is a single-center phase II study that aims to evaluate the antitumor activity of the combination of imatinib mesylate and gemcitabine in patients with unresectable MPM expressing PDGFR-beta or C-kit by immunohistochemistry (IHC) .
The principal investigator of the study is Dr. Paul Zucali, and the protocol will be activated at the 'Istituto Clinico Humanitas, Rozzano (Milan).